UNSPSC 51191967: L-ornitin/ L-aspartate

L-ornithine-L-aspartate (LOLA) is a salt of two nonessential L-amino acids: ornithine and aspartic acid. It is used as a medicinal product to lower blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.

UNSPSC 51191967 L-ornithine / L-aspartate is a Commodity code that names a single pharmaceutical product line — amino acid formulations used in medical and clinical settings. State and local governments procure this product primarily through health departments, county health systems, fire and EMS departments, and forensic laboratories for clinical use, emergency medical services, and toxicology testing. The recent solicitations tagged under this code, however, show substantial scope misalignment: the code appears in notices for opioid settlement grant awards (Bernalillo County), forensic drug reference standards (Pinellas County), Naloxone and drug deactivation systems (Seminole County), BLS/ALS pharmaceuticals and EMS supply vending (Tucson), and general health clinic services (Collier County). Only the Pinellas County forensic lab procurement and the Seminole County Naloxone purchase represent pharmaceutical acquisitions; the others cover either grants, clinical services, or emergency response equipment unrelated to L-ornithine / L-aspartate specifically. The issuing bodies span county health departments, fire departments, and special forensic programs across Florida, Arizona, and Minnesota cooperative purchasing.

The code shows limited direct activity for L-ornithine / L-aspartate itself. Pinellas County's forensic laboratory procurement (ITQ 26-0305-ITQ, posted April 23, 2026, due April 23, 2026) sought certified reference materials and drug standards for forensic analysis under the Paul Coverdell Forensic Sciences Improvement Act Program, but this procurement targets forensic standards rather than clinical L-ornithine / L-aspartate formulations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued a multistate RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, posted January 20, 2026, due March 26, 2026) covering 50 states and territories, but the RFP scope focuses on common generics and OTC items distributed through three authorized wholesalers, with no specific mention of amino acid formulations. Seminole County's procurement (IFB 60459723LAS, posted June 30, 2026, due July 26, 2023) sought Naloxone and drug deactivation systems for community health, not L-ornithine / L-aspartate. The code's recent notice volume is dominated by networking events (trade shows, vendor forums, open houses) and administrative announcements (office relocations) that do not represent procurement activity. Geographic activity is scattered across Florida, Arizona, Minnesota, and Texas, with no concentration in any region. The code warrants close attention only if pursuing forensic reference materials or if clinical use of L-ornithine / L-aspartate appears in future health department or EMS procurement rounds; current signals do not support active pursuit under this code.